| Drug Name |
Sulindac |
| Drug ID |
BADD_D02097 |
| Description |
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2. |
| Indications and Usage |
For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis. |
| Marketing Status |
approved; investigational |
| ATC Code |
M01AB02 |
| DrugBank ID |
DB00605
|
| KEGG ID |
D00120
|
| MeSH ID |
D013467
|
| PubChem ID |
1548887
|
| TTD Drug ID |
D0Z5IU
|
| NDC Product Code |
0591-5661; 17337-0541; 24658-771; 0591-5660; 24658-770; 63629-3208; 49452-7583; 42806-018; 50090-2093; 55700-682; 53489-478; 0904-6217; 53489-479; 0904-6216; 52133-0007; 55111-059; 42806-011; 71335-0413; 55289-930; 71205-648 |
| UNII |
184SNS8VUH
|
| Synonyms |
Sulindac | Apo-Sulin | Apo Sulin | Arthrobid | Clinoril | Arthrocine | Klinoril | Sulindal | Chibret | Kenalin | MK-231 | MK 231 | MK231 | Novo-Sundac | Novo Sundac | Nu-Sulindac | Nu Sulindac | Aclin | Copal |
